Zobrazeno 1 - 10
of 63
pro vyhledávání: '"J.F. Héron"'
Autor:
Florence Joly, C. Delcambre, Audrey Faveyrial, Elodie Coquan, Sophie Gouérant, M.P. Galais, Katharina Gunzer, Laure Kaluzinski, Emmanuel Sevin, Florence Polycarpe, Gilles Saucier, Julie Vanbockstael, Ioana Hrab, Radj Gervais, A.-C. Lefebvre, Michel André, Bénédicte Clarisse, Jean-Michel Grellard, J.F. Héron, D. Allouache, Sabine Noal, Brigitte Vie, Noëmie Lemenand, Audrey Emmanuelle Dugué
Publikováno v:
Supportive Care in Cancer. 24:1131-1138
Chemotherapy-induced nausea and vomiting (CINV) still remain frequent. The procedure for announcing the diagnosis (PAD) was an emblematic measure of the first French Plan Cancer aiming at providing patients with time to listen, information after canc
Autor:
J.E. Couette, J.F. Héron, Michel Henry-Amar, Florence Joly, P. Bottet, N. Allouache, D. Brune, J. Macé-Lesec’h, L. Kalusinski, J. Pény
Publikováno v:
Journal of Clinical Oncology. 20:73-80
PURPOSE: To evaluate quality of life and social problems in long-term survivors of testicular cancer. PATIENTS AND METHODS: In 1998, 71 testicular cancer survivors (cases) identified from the Calvados General Tumor Registry were enrolled onto a case-
Publikováno v:
British Journal of Cancer
Our purpose was to evaluate the late physical and psychosocial difficulties of premenpausal patients treated for a localized breast cancer and to weigh the impact of chemotherapy on long-term quality of life. Two self-administered questionnaires, the
Autor:
Catherine Lhommé, Moïse Namer, Jean-Paul Guastalla, F. Chauvin, P. Goupil, J.F. Héron, P. Charrot, P. Kerbrat, M. Chazard, I. Richard, F. Mayer
Publikováno v:
Annals of Oncology. 5:127-132
Summary Background Because of its antitumour activity and its pharmacological advantage when administered by the intraperitoneal route, carboplatin was studied in a phase II multicen-tric trial. The aim of the study was to determine the response rate
Autor:
J. Macé-Lesec'h, D. Lebrun-Jezekova, P. Chinet-Charrot, J.F. Héron, P. Kerbrat, Florence Joly, H. Crouet, Catherine Lhommé, D. Vennin, M. Rios, J. Chauvergne, A. Goupil, F. Mayer
Publikováno v:
Gynecologic oncology. 78(3 Pt 1)
The aim of this study was to evaluate the impact of platinum dose intensity on pathological response rate and overall survival in patients with advanced ovarian adenocarcinoma.Between February 1992 and December 1996, 195 previously untreated patients
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 9(7)
Summary Purpose: To evaluate late physical and psychosocial sequelae in patients treated with an association of external beam irradiation (EBI) and brachytherapy (BT) for localized prostate cancer. Patients and methods: Seventy-one patients free of d
Autor:
J.E. Couette, H. Crouet, J. De Ranieri, D. Brune, Michel Henry-Amar, VH Ly, J.F. Héron, D Benabid, F. Lesaunier
Publikováno v:
Cancer/Radiothérapie. 1:590-591
Publikováno v:
European Journal of Cancer. 33:S33-S34
Publikováno v:
European Journal of Cancer. 31:S241
The efficiency of MVAC (Methotrexate 30 mg/m 2 J 1 –J 15 –J J22 , Vinblastine 3 mg/m 2 J l , Doxorubicine 40 mg/m 2 J 1 , Cisplatin 70 mg/m 2 J 1 ) given as neoadjuvant chemotherapy (CT), was evaluated in a series of newly diagnosed patients trea
Autor:
Thomas Bachelot, F. Oberling, M. Chazard, M. Schreinerova, I. Pruvot, P. Vennin, J.P. Guastalla, J-M Ferrero, Pierre Pouillart, F. Garat, Moïse Namer, M.A. Chanez, P. Kerbrat, B. Pellae-Cosset, P. Dufour, Pierre Fumoleau, P Soler-Michel, Catherine Lhommé, J.F. Héron, N. Tubiana, J. Fleury, Roland Bugat, Véronique Diéras, Jacques Dauplat
Publikováno v:
European Journal of Cancer. 31:S108
Eligibility criteria histologically proven OC, measurable/evaluable disease, relapse/progression after at least one platinum based CT, ≤ 3 prior CT. Treatment 1 or 2 prior CT, T = 175 mg/m2 [Group A (A) = 151 pts]; 3 prior CT, T = 135 mg/m2 [Group